Omadacycline mesylate

For research use only. Not for therapeutic Use.

  • CAT Number: I000717
  • CAS Number: 1196800-40-4
  • Molecular Formula: C30H44N4O10S
  • Molecular Weight: 652.76
  • Purity: ≥95%
Inquiry Now

Omadacycline Mesylate(Cat No.:I000717)is a modern tetracycline-class antibiotic designed to treat a variety of bacterial infections, including community-acquired bacterial pneumonia and skin infections. It works by inhibiting bacterial protein synthesis through binding to the 30S ribosomal subunit, which blocks amino acid addition. Omadacycline is effective against both Gram-positive and Gram-negative bacteria, including strains resistant to traditional antibiotics, such as MRSA and certain Enterobacteriaceae. Its oral and intravenous formulations offer flexible dosing, making it a valuable option for outpatient and inpatient care. Omadacycline mesylate addresses rising antibiotic resistance, enhancing therapeutic options.


Catalog Number I000717
CAS Number 1196800-40-4
Synonyms

(4S,4aS,5aR,12aS)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-9-((neopentylamino)methyl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide methanesulfonate

Molecular Formula C30H44N4O10S
Purity ≥95%
Target Bacterial
Solubility 10 mM in DMSO
Storage Store at -20°C
IC50 N/A
IUPAC Name (4S,4aS,5aR,12aR)-4,7-bis(dimethylamino)-9-[(2,2-dimethylpropylamino)methyl]-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide;methanesulfonic acid
InChI InChI=1S/C29H40N4O7.CH4O3S/c1-28(2,3)12-31-11-14-10-17(32(4)5)15-8-13-9-16-21(33(6)7)24(36)20(27(30)39)26(38)29(16,40)25(37)18(13)23(35)19(15)22(14)34;1-5(2,3)4/h10,13,16,21,31,34-35,38,40H,8-9,11-12H2,1-7H3,(H2,30,39);1H3,(H,2,3,4)/t13-,16-,21-,29-;/m0./s1
InChIKey BRTZQVQPPVIFKG-XGLFQKEBSA-N
SMILES CC(C)(C)CNCC1=CC(=C2C[C@H]3C[C@H]4[C@@H](C(=O)C(=C([C@]4(C(=O)C3=C(C2=C1O)O)O)O)C(=O)N)N(C)C)N(C)C.CS(=O)(=O)O
Reference

<p style=/line-height:25px/>
<br>[1]. Schmitz J, Holzgrabe U. Amadacyclin – a new tetracycline antibiotic in the pipeline. Pharm Unserer Zeit. 2010 Mar;39(2):94-5.
</p>

Request a Quote